Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

COLLABORATE CORPORATION LIMITED

ABN

60 066 153 982

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1	+Class of +securities issued or to be issued	(a) **Shares;** (b) **CL8O Options;** (c) **Shares;** (d) **CL8O Options;** (e) **CL8O Options and** (f) **Facility Options.**
2	Number of +securities issued or to be issued (if known) or maximum number which may be issued	(a) **2,380,952 Shares;** (b) **793,651 CL8O Options;** (c) **11,111,111 Shares;** (d) **3,703,704 CL8O Options;** (e) **1,833,333 CL8 Options;** (f) **1,700,000 Facility Options.**
3	Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)	(a) **Fully paid ordinary shares ("Shares");** (b) **Options exercisable at $0.02 each on or before 30 April 2017 ("CL8O Options");** (c) **Shares;** (d) **CL8O Options;** (e) **CL8O Options;** (f) **Options exercisable at $0.03 per Option on or before 31 May 2019 ("Facility Options").**

+ See chapter 19 for defined terms.

4	Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	**(a) Shares – Yes.** **(b) CL8O Options – Yes;** **(c) Shares – Yes;** **(d) CL8O Options – Yes;** **(e) CL8O Options – Yes;** **(f) Facility Options – No. Options over unissued shares may only be exercised in accordance with the terms and conditions. Upon conversion of the options to shares, the shares will rank equally with existing shares.**
5	Issue price or consideration	**(a) $0.021 per Share;** **(b) Nil;** **(c) $0.018 per Share;** **(d) Nil;** **(e) Nil;** **(f) Nil.**
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	**(a) The funds from Tranche 2 of the December 2015 Placement will be used towards driving the growth of DriveMyCar, MyCaravan and Rentoid websites through marketing, PR and product development activities, supporting the development and monetisation of the PeerPass trust and reputation platform, pursuing investment opportunities that align with the Company's peer-to-peer strategy, for general working capital and to cover costs of the placement** **(b) CL8O Options were issued on a 1-for-3 basis to the investor in Tranche 2 of the December 2015 Placement.** **(c) The funds from Tranche 2 of the May 2016 Placement will principally be used to grow Collaborate's peer-to-peer marketplaces through marketing, PR and product development activities and**

+ See chapter 19 for defined terms.

		supplement the Company's general working capital.
		(d) CL8O Options were issued on a 1-for-3 basis to investors in Tranche 2 of the May 2016 Placement.
		(e) CL8O Options were issued on a 1-for-3 basis to investors in Tranche 2 of the May 2016 Placement.
		(f) The Facility Options have been issued in recognition of the support of subscribers to agreements for equity facilities totalling $2.25 million, the terms of which were announced on 28 June 2016.
6a	Is the entity an ⁺eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h *in relation to the ⁺securities the subject of this Appendix 3B*, and comply with section 6i	**Yes.**
6b	The date the security holder resolution under rule 7.1A was passed	**30 November 2015.**
6c	Number of ⁺securities issued without security holder approval under rule 7.1	**Nil.**
6d	Number of ⁺securities issued with security holder approval under rule 7.1A	**Nil.**
6e	Number of ⁺securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	**(e) 1,833,333 CL8O Options approved at EGM held on 10 August 2016.**
6f	Number of securities issued under an exception in rule 7.2	**(a) 2,380,952 Shares;** **(b) 793,651 CL8O Options;** **(c) 11,111,111 Shares;** **(d) 3,703,704 CL8O Options; and** **(f) 1,700,000 Facility Options.**

+ See chapter 19 for defined terms.

6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	**Not applicable.**
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	**Not applicable.**
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	**Rule 7.1:** 45,707,319 **Rule 7.1A:** 38,366,581
7	Dates of entering ⁺securities into uncertificated holdings or despatch of certificates	**12 August 2016**

		Number	⁺Class
8	Number and ⁺class of all ⁺securities quoted on ASX (*including* the securities in section 2 if applicable)	**392,708,365**	**Fully paid ordinary shares.**
		172,089,484	**Options exercisable at $0.02 each on or before 30 April 2017.**

Number	+Class
5,000,000	**Options exercisable at $0.02 each on or before 2 October 2017.**
2,500,000	**Options exercisable at $0.03 each on or before 2 October 2017.**
883,334	**Executive A Options exercisable at $0.02 each on or before 28 November 2018**
883,333	**Executive A Options exercisable at $0.02 each on or before 28 November 2019**
883,333	**Executive A Options exercisable at $0.02 each on or before 28 November 2020**
883,334	**Executive B Options exercisable at $0.03 each on or before 28 November 2018**
883,333	**Executive B Options exercisable at $0.03 each on or before 28 November 2019**
883,333	**Executive B Options exercisable at $0.03 each on or before 28 November 2020**
2,000,000	**Director Options exercisable at $0.03 each on or before 28 November 2018**
5,000,000	**Officer Options exercisable at $0.035 each on or before 30 November 2018**
4,500,000	**Facility Options exercisable at $0.03 each on or before 31 May 2019**

9   Number and +class of all +securities not quoted on ASX (*including* the securities in section 2 if applicable)

+ See chapter 19 for defined terms.

10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	**Not applicable.**

Part 2 - Bonus issue or pro rata issue

Questions 11 to 33 Not Applicable

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34   Type of +securities
(*tick one*)

(a)   ☒   +Securities described in Part 1 – **Shares and CL8O Options.**

(b)   ☒   All other +securities – **Facility Options.**

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Questions 35 to 37 - Not Applicable

Entities that have ticked box 34(b)

Questions 38 to 42 - Not Applicable

+ See chapter 19 for defined terms.

Quotation agreement

1	⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.

2	We warrant the following to ASX.

- The issue of the ⁺securities to be quoted complies with the law and is not for an illegal purpose.

- There is no reason why those ⁺securities should not be granted ⁺quotation.

- An offer of the ⁺securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

  Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any ⁺securities to be quoted and that no-one has any right to return any ⁺securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the ⁺securities be quoted.

- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.

3	We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4	We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before ⁺quotation of the ⁺securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: .... Date: **12 August 2016**
	Company Secretary

Print name:	**Karen Logan**

== == == == ==

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for +eligible entities

Introduced 01/08/12

Part 1

Rule 7.1 – Issues exceeding 15% of capital
Step 1: Calculate "A", the base figure from which the placement capacity is calculated

Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	308,605,647
Add the following: • Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2	16,417,307 • 2,925,244 Shares issued on 2 September 2015, exception 4; • 2,380,952 Shares issued on 12 August 2016, exception 14; and • 11,111,111 Shares issued on 12 August 2016, exception 14.
• Number of fully paid ordinary securities issued in that 12 month period with shareholder approval	58,642,857 • 25,000,000 Shares issued on 27 August 2015, shareholder approval under Rule 7.1 given at EGM held 5 June 2015; • 28,142,857 Shares issued on 22 December 2015, shareholder approval under Rule 7.1 given at EGM held 10 August 2016; and • 5,500,000 Shares issued on 4 May 2016, shareholder approval under Rule 7.1 given at EGM held 10 August 2016.
• Number of partly paid ordinary securities that became fully paid in that 12 month period *Note:* • *Include only ordinary securities here – other classes of equity securities cannot be added*	Nil

• *Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed* • *It may be useful to set out issues of securities on different dates as separate line items*	
Subtract the number of fully paid ordinary securities cancelled during that 12 month period	Nil
"A"	383,665,811

Step 2: Calculate 15% of "A"	
"B"	0.15 *[Note: this value cannot be changed]*
Multiply "A" by 0.15	57,549,872

Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used	
Insert number of equity securities issued or agreed to be issued in that 12 month period *not counting* those issued: • Under an exception in rule 7.2 • Under rule 7.1A • With security holder approval under rule 7.1 or rule 7.4 *Note:* • *This applies to equity securities, unless specifically excluded – not just ordinary securities* • *Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed* • *It may be useful to set out issues of securities on different dates as separate line items*	11,842,553 • 2,800,000 Facility Options exercisable at $0.03 each on or before 31 May 2019 issued on 28 June 2016. • 9,042,553 Shares issued on 18 July 2016.
"C"	11,842,553

Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1	
"A" x 0.15 *Note: number must be same as shown in Step 2*	57,549,872
Subtract "C"	11,842,553

+ See chapter 19 for defined terms.

Note: number must be same as shown in Step 3	
Total ["A" x 0.15] – "C"	45,707,319 *[Note: this is the remaining placement capacity under rule 7.1]*

Part 2

Rule 7.1A – Additional placement capacity for eligible entities	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
"A" *Note: number must be same as shown in Step 1 of Part 1*	383,665,811
Step 2: Calculate 10% of "A"	
"D"	0.10 *Note: this value cannot be changed*
Multiply "A" by 0.10	38,366,581
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used	
Insert number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A *Notes:* • *This applies to equity securities – not just ordinary securities* • *Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed* • *Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained* • *It may be useful to set out issues of securities on different dates as separate line items*	Nil
"E"	Nil

+ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10 *Note: number must be same as shown in Step 2*	38,366,581
Subtract "E" *Note: number must be same as shown in Step 3*	Nil
Total ["A" x 0.10] – "E"	38,366,581 *Note: this is the remaining placement capacity under rule 7.1A*

+ See chapter 19 for defined terms.